Clearline Capital LP Adma Biologics, Inc. Transaction History

Clearline Capital LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.03 - $2.86 $856,584 - $1.21 Million	-421,963 Reduced 14.46%	2,496,297 $6.07 Million
Q2 2022 Aug 15, 2022	SELL	$1.43 - $2.2 $3.17 Million - $4.88 Million	-2,219,597 Reduced 43.2%	2,918,260 $5.78 Million
Q1 2022 May 16, 2022	SELL	$1.28 - $1.83 $1.55 Million - $2.22 Million	-1,212,837 Reduced 19.1%	5,137,857 $9.4 Million
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.66 $6.11 Million - $9.3 Million	5,603,249 Added 749.65%	6,350,694 $8.95 Million
Q3 2021 Nov 15, 2021	SELL	$1.13 - $1.65 $197,831 - $288,868	-175,072 Reduced 18.98%	747,445 $845,000
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.07 $867,402 - $1.19 Million	574,439 Added 165.03%	922,517 $1.48 Million
Q1 2021 May 17, 2021	BUY	$1.67 - $2.95 $581,290 - $1.03 Million	348,078 New	348,078 $613,000

319

185M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.91B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Clearline Capital LP, based on Form 13F filings with the SEC.

Stay updated on Clearline Capital LP with notifications on news.